Evidence map›Paper›PMID 29956017›Full record

ArticleAngiogenesis2018

Heparin impairs angiogenic signaling and compensatory lung growth after left pneumonectomy.

Duy T Dao, Lorenzo Anez-Bustillos, Jared Ourieff, Amy Pan, Paul D Mitchell, Hiroko Kishikawa, Gillian L Fell, Meredith A Baker, Randolph S Watnick, Hong Chen and 4 more

Abstract read
In one paragraph

Article in Angiogenesis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. New anti-angiogenic compound based on chemically modified heparin.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Duy T DaoVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Lorenzo Anez-BustillosVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Jared OurieffVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Amy PanVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Paul D MitchellInstitutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA, 02115, USA.
Hiroko KishikawaVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Gillian L FellVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Meredith A BakerVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Randolph S WatnickVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Hong ChenVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Thomas E HamiltonDepartment of Surgery, Boston Children's Hospital, Harvard Medical School, 300 Longwood Ave, Fegan 3, Boston, MA, 02115, USA.
Michael S RogersVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Diane R BielenbergVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Mark PuderVascular Biology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. Mark.Puder@childrens.harvard.edu.
Harvard University · USBoston Children's Hospital · US

Funding

HARVARD-LONGWOOD RESEARCH TRAINING IN VASCULAR SURGERYT32HL007734 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI FERRAN, CHRISTIANE, LOGERFO, FRANK W · 1993 to 2023
$10.5M
Mouse Neurodevelopmental Behavior CoreU54HD090255 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI SAHIN, MUSTAFA · 2016 to 2020
$5.2M
Generation and use of lipid emulsions to understand mechanisms of and optimally manage parenteral nutrition associated liver diseaseF32DK104525 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI FELL, GILLIAN LYNAPP · 2014 to 2016
$163k
NHLBI NIH HHS T32 HL007734NICHD NIH HHS U54 HD090255NIDDK NIH HHS F32 DK104525NIH HHS 1F32DK104525NIH HHS 5T32HL007734
6 · The paper itself

Abstract

Children with hypoplastic lung diseases, such as congenital diaphragmatic hernia, can require life support via extracorporeal membrane oxygenation and systemic anticoagulation, usually in the form of heparin. The role of heparin in angiogenesis and organ growth is inconclusive, with conflicting data reported in the literature. This study aimed to investigate the effects of heparin on lung growth in a model of compensatory lung growth (CLG). Compared to the absence of heparin, treatment with heparin decreased the vascular endothelial growth factor (VEGF)-mediated activation of VEGFR2 and mitogenic effect on human lung microvascular endothelial cells in vitro. Compared to non-heparinized controls, heparinized mice demonstrated impaired pulmonary mechanics, decreased respiratory volumes and flows, and reduced activity levels after left pneumonectomy. They also had lower lung volume, pulmonary septal surface area and alveolar density on morphometric analyses. Lungs of heparinized mice displayed decreased phosphorylation of VEGFR2 compared to the control group, with consequential downstream reduction in markers of cellular proliferation and survival. The use of bivalirudin, an alternative anticoagulant that does not interact with VEGF, preserved lung growth and pulmonary mechanics. These results demonstrated that heparin impairs CLG by reducing VEGFR2 activation. These findings raise concern for the clinical use of heparin in the setting of organ growth or regeneration.

Indexed as

PneumonectomyAnimalsCell ProliferationCell SurvivalHeparinHirudinsHumansLungMaleMicePeptide FragmentsRecombinant ProteinsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2bivalirudinHeparinHirudinsKdr protein, mousePeptide FragmentsRecombinant ProteinsVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouseVascular Endothelial Growth Factor Receptor-2BivalirudinCompensatory lung growthHeparinPneumonectomyVascular endothelial growth factor

Identifiers

PMID29956017
PMCPMC6463887
OpenAlexW2810728443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.